Zentalis Pharmaceuticals, Inc. Overview
Pro stress-test →Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer treatment, with its lead program azenosertib in Phase 3 clinical trials for ovarian cancer and other tumor types. The company targets fundamental cancer biology pathways through its integrated discovery engine approach.
Strategic Profile
Pro stress-test →The company is developing azenosertib as a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer. The Phase 2 DENALI trial remains on track with topline data expected by year-end 2026 with potential to support accelerated approval.
Competitive Landscape
Pro stress-test →Competitors include ORIC Pharmaceuticals, Prelude Therapeutics, Hookipa Pharma, Ayala Pharmaceuticals, and Enliven Therapeutics. Zentalis differentiates through its WEE1 inhibitor approach and biomarker-driven patient selection strategy targeting Cyclin E1-positive populations in platinum-resistant ovarian cancer.
Industry Context
Zentalis Pharmaceuticals, Inc. operates in Biotechnology / Oncology.
Key facts
Founded: 2014 · Headquarters: San Diego, CA, United States · Employees: 166 · Revenue: $26.9M · Market cap: $152M